José Ignacio López Villalba-rekin lankidetzan egindako argitalpenak (88)

2024

  1. Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis

    Immuno-Oncology and Technology, Vol. 21

  2. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management

    Cancers

2022

  1. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level

    Current Urology Reports, Vol. 23, Núm. 6, pp. 93-97

  2. Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic

    Cancers

2021

  1. (Pro)renin receptor is a novel independent prognostic marker in invasive urothelial carcinoma of the bladder

    Cancers, Vol. 13, Núm. 22

  2. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  3. Mimickers of urothelial carcinoma and the approach to differential diagnosis

    Clinics and Practice, Vol. 11, Núm. 1, pp. 110-123

  4. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

  5. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments

    Cancers, Vol. 13, Núm. 9

2020

  1. Altered tissue and plasma levels of fibroblast activation protein-α (FAP) in renal tumours

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

    Current Urology Reports, Vol. 20, Núm. 1

  2. Common and uncommon features of nephrogenic adenoma revisited

    Pathology Research and Practice, Vol. 215, Núm. 10

  3. Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology

    npj Precision Oncology, Vol. 3, Núm. 1

  4. Precise immunodetection of PTEN protein in human neoplasia

    Cold Spring Harbor Perspectives in Medicine, Vol. 9, Núm. 12

  5. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder

    Human Pathology, Vol. 91, pp. 61-68

2018

  1. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 27-30

  2. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 89-93

  3. Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma

    Current Urology Reports, Vol. 19, Núm. 1

  4. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy

    Pathology Research and Practice, Vol. 214, Núm. 8, pp. 1110-1114